Earlier today, I published a critique of a news story that was imbalanced in its reporting about pre-diabetes. The story referred to a “national health crisis.”
In his weekly BMJ blog reviewing journals, Dr. Richard Lehman addressed other hyperbolic language used to describe Type 2 diabetes. He wrote:
In the catastrophizing parlance of the Lancet, type 2 diabetes is sometimes described as a “public health emergency.” If people must use this kind of language, they should really be more careful to distinguish between a challenge, a problem, a disaster, and an emergency. Describing the rise in type 2 diabetes as an emergency suits pharmaceutical companies because they want to sell drugs for diabetes without waiting for substantive proof of long term benefit. I have made this point so often that I will let you off for yawning. But what have we here? A systematic review of glucagon like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes, which reads more like an advertising hoarding than a scientific paper. “GLP-1 agonist and basal insulin combination treatment can enable achievement of the ideal trifecta in diabetic treatment: robust glycaemic control with no increased hypoglycaemia or weight gain. This combination is thus a potential therapeutic strategy that could improve the management of patients with type 2 diabetes.” It’s so wonderful that they’ve even had to make up a new word to describe it. I think “trifecta” means something that has three effects, but there’s one fecta that counts above all in type 2 diabetes: reduction of vascular end points. And I excuse you a second yawn, but I just have to keep saying this as long as papers of this sort find their way into high impact journals.
Catastrophizing parlance – about national health crises, public health emergencies, etc.
That’s what we get in some medical journal articles.
That’s what we get in some journalism.
Is it any wonder we have the poor public dialogue that we have about health care? Read some of the reader comments left in response to the news story I mentioned at the top. Some of what I saw:
————————
Follow us on Twitter:
https://twitter.com/garyschwitzer
https://twitter.com/healthnewsrevu
Opinions on other issues in news, journals, PR, advertising, marketing
A lot of interesting workshops are happening now at the #NBCCSummit! @garyschwitzer, the publisher of @HealthNewsRevu, is discussing new cancer research news. #BeBold
Comments
Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.
Comments are closed.
Our Comments Policy
But before leaving a comment, please review these notes about our policy.
You are responsible for any comments you leave on this site.
This site is primarily a forum for discussion about the quality (or lack thereof) in journalism or other media messages (advertising, marketing, public relations, medical journals, etc.) It is not intended to be a forum for definitive discussions about medicine or science.
We will delete comments that include personal attacks, unfounded allegations, unverified claims, product pitches, profanity or any from anyone who does not list a full name and a functioning email address. We will also end any thread of repetitive comments. We don”t give medical advice so we won”t respond to questions asking for it.
We don”t have sufficient staffing to contact each commenter who left such a message. If you have a question about why your comment was edited or removed, you can email us at feedback@healthnewsreview.org.
There has been a recent burst of attention to troubles with many comments left on science and science news/communication websites. Read “Online science comments: trolls, trash and treasure.”
The authors of the Retraction Watch comments policy urge commenters:
We”re also concerned about anonymous comments. We ask that all commenters leave their full name and provide an actual email address in case we feel we need to contact them. We may delete any comment left by someone who does not leave their name and a legitimate email address.
And, as noted, product pitches of any sort – pushing treatments, tests, products, procedures, physicians, medical centers, books, websites – are likely to be deleted. We don”t accept advertising on this site and are not going to give it away free.
The ability to leave comments expires after a certain period of time. So you may find that you’re unable to leave a comment on an article that is more than a few months old.
You might also like